Jiang Wenbin 4

What Happened
Jiang Wenbin, President, CEO and a director of Cytek Biosciences (CTKB), had multiple Restricted Stock Units (RSUs) vest/convert on May 18, 2026, resulting in the acquisition of 80,062 shares. To satisfy tax withholding obligations, 25,542 of those shares were withheld and surrendered to the issuer for a total withholding value of $90,674 (withholding price shown as $3.55/share). The derivative-line $0 disposals reflect the conversion/settlement of RSUs into common stock rather than a cash sale.

Key Details

• Transaction date: May 18, 2026; Form 4 filed May 20, 2026 (timely filing).
• Acquired (RSU conversions): 7,854 + 14,733 + 19,334 + 38,141 = 80,062 shares.
• Withheld/surrendered for taxes: 1,913 + 3,588 + 5,032 + 15,009 = 25,542 shares; withholding price $3.55/share; total ~$90,674.
• Net shares added to beneficial ownership from these events: 80,062 − 25,542 = 54,520 shares.
• Transaction codes: M = exercise/conversion of derivative (RSU conversion), F = payment of tax liability via share withholding.
• Footnotes: F1–F6 describe that these are RSUs (one RSU = one share) and detail multi‑year vesting schedules; F2 confirms shares were surrendered to satisfy tax withholding.
• Shares owned after the transaction: not specified in the filing.

Context
This was not an open‑market purchase or a sale to generate cash; it was the scheduled vesting/conversion of RSUs with shares withheld to cover taxes (a common, non‑sentiment transaction). For retail investors, note this increases the insider's net holdings by the net amount listed above, but it does not necessarily signal a bullish trading decision — it reflects compensation vesting and routine tax withholding.